Selected article for: "enzymatic activity and proteolytic activity"
Author: Lu, Jinghua; Sun, Peter D; Sun, Peter D.
Title: High affinity binding of SARS-CoV-2 spike protein enhances ACE2 carboxypeptidase activity.
  • Cord-id: sohyuvwk
  • Document date: 2020_12_25
    • ID: sohyuvwk
    Snippet: The novel severe acute respiratory syndrome coronavirus (SARS-CoV-2) has emerged to a pandemic and caused global public health crisis. Human angiotensin-converting enzyme 2(ACE2) was identified as the entry receptor for SARS-CoV-2. As a carboxypeptidase, ACE2 cleaves many biological substrates besides angiotensin II to control vasodilatation and vascular permeability. Given the nanomolar high affinity between ACE2 and SARS-CoV-2 spike protein, we investigated how this interaction would affect th
    Document: The novel severe acute respiratory syndrome coronavirus (SARS-CoV-2) has emerged to a pandemic and caused global public health crisis. Human angiotensin-converting enzyme 2(ACE2) was identified as the entry receptor for SARS-CoV-2. As a carboxypeptidase, ACE2 cleaves many biological substrates besides angiotensin II to control vasodilatation and vascular permeability. Given the nanomolar high affinity between ACE2 and SARS-CoV-2 spike protein, we investigated how this interaction would affect the enzymatic activity of ACE2. Surprisingly, SARS-CoV-2 trimeric spike protein increased ACE2 proteolytic activity ∼3-10 fold against model peptide substrates, such as caspase-1 substrate and Bradykinin-analog. The enhancement in ACE2 enzymatic function was mediated by the binding of SARS-CoV-2 spike RBD domain. These results highlighted the potential for SARS-CoV-2 infection to enhance ACE2 activity, which may be relevant to the cardiovascular symptoms associated with COVID-19.

    Search related documents:
    Co phrase search for related documents
    • absence presence and active peptide: 1
    • absence presence and active site: 1, 2, 3, 4, 5, 6, 7, 8
    • absence presence and acute sars respiratory syndrome coronavirus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37
    • absence presence and lung fluid: 1
    • absence presence and lysine residue: 1
    • ace angiotensin convert enzyme and acute sars respiratory syndrome coronavirus: 1
    • active conformation and acute sars respiratory syndrome coronavirus: 1, 2, 3, 4, 5, 6, 7
    • active peptide and acute sars respiratory syndrome coronavirus: 1, 2, 3
    • active site and acute sars respiratory syndrome coronavirus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72
    • active site and lysine residue: 1, 2
    • active site bind and acute sars respiratory syndrome coronavirus: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • active substrate and acute sars respiratory syndrome coronavirus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • active substrate and lysine residue: 1
    • acute sars respiratory syndrome coronavirus and lung fluid: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • acute sars respiratory syndrome coronavirus and lung fluid accumulation: 1, 2
    • acute sars respiratory syndrome coronavirus and lung type ii pneumocyte: 1, 2
    • acute sars respiratory syndrome coronavirus and lysine residue: 1, 2, 3, 4, 5